You are now leaving the Haemonetics U.S. website, click 'Yes' to continue or 'No' to stay on the U.S. website.
"BloodTrack® has fundamentally transformed our ability to deliver blood products by creating a more efficient process whereby blood is ordered just on time, and only when needed. This point-of-care solution has helped us significantly reduce unnecessary ordering and transfusing while realizing cost
savings and enhancing patient care.”
Anesthesiologist & Transfusion Committee Member, mid-Atlantic region hospital, USA, 07.2016
"Haemonetics has been a reliable partner in patient blood management at the RKU since 1985. The design and development of the Ulm Autologous Transfusion Concept (ATU) was made possible largely because of the company's wide portfolio both in apheresis and in automated autologous transfusion. Many innovative developments were only possible due to our clinical experience combined with the technical equipment of Haemonetics, and thanks to a highly productive cooperative approach."
Dr. Peter M. Geiger, Medical Director, RKU University and Rehabilitation Hospitals, Ulm, Germany, 03.2013
"As part of the tender process we evaluated Haemonetics' newest advancement in autotransfusion systems, the Cell Saver Elite. One of the key criteria for the evaluation was the haematocrit level of the resulting blood product. We performed quality control tests for this purpose and the average level was 62%. This result was above the level of range that we were expecting, hence we are extremely satisfied."
Ian Brown, Senior ODP, James Cook Hospital, Middlesborough, UK, 12.2012
"Haemonetics’ solutions helped us develop an effective autologous blood management program. The OrthoPAT system is a powerful tool that supports us to provide safe and secure medical care benefits to our patients in joint reconstructive surgery."
Kazuo Hirakawa, Hospital Director, and Takeshi Kaneko, Department of Orthopedics, Shonan Kamakura Joint Reconstruction Center’s, Japan, 04.2010
"We will continue to use the OrthoPAT System on THA and TKA cases as part of our blood management program. We believe Haemonetics’ solution has had an impact on the number of patients needing transfusions, by reducing the number of allogeneic transfusions, and thereby increasing safety in orthopedic surgeries."
Takashi Nakamura, Department Lecturer, Toho University Omori Medical Center, Japan, 04.2010
"The OrthoPAT system is efficient, cost effective and gives me the confidence to tell patients, ‘I won’t have to give you any blood except your own.’ ”
Stuart Gordon, M.D. Orthopedic Surgeon, USA, 07.2011
"Quite frankly, I was overwhelmed with how much of a difference using the OrthoPAT made. Having the data to back it up really drove the point home and reinforced that what we were seeing in practice was real."
Dr. Steven Jones, Orthopedic Surgeon, USA, 05.2011
"I knew the device was doing some really good things for the patients and the blood bank, but the numbers really backed up what I thought was going on… I haven’t seen another machine out there that does what the OrthoPAT does… it’s just a really good product.”
Damian Loehle, Operating Room Nurse, USA, 07.2011
"I am pleased that the Haemonetics TEG system solves one of our blood management challenges. The TEG system helps us reduce unnecessary blood transfusions, thus helping us provide better care to our patients and economic savings to our hospital."
Dr. Tsou Mei-Yung, Chief, Taiwan, 04.2009
"With the cooperation of Haemonetics, we changed our blood management program in 2005 to our significant benefit. By eliminating preoperative blood donation and using OrthoPAT and Cell Saver extensively, we achieved a remarkable reduction in homologous blood units—up to 160 units less per year—which works out to about a savings of 50,000 € for the hospital over three years. Our blood management practice will continue in this direction for the future, with Haemonetics as our partner."
Dr. F-J. Unterburger, Head of Department, Germany, 04.2009
"For over 25 years, we have enjoyed an excellent relationship with Haemonetics. During this time we have always been pleased with the company’s devices, disposables and consultation services. Together, Haemonetics solutions and personal contact with the company’s representatives have helped RKU develop an effective and profitable autologous blood management program that has benefited our patients."
Dr. Peter Geiger, Head of Department of Anesthesiology and Intensive Care Medicine, Germany, 04.2009
"The efficiency of the products using the Haemonetics bags has doubled. With the Acrodose™ Pooling Methodology we are able to now manufacture a platelet pool with 4.5 units of platelets. Compare that to just 20 years ago when we used to use 10 units of platelets. These efficiencies enable us to manufacture more therapeutic doses of platelets from the same number of platelet concentrates … enabling us to do more with less.”
Alicia Prichard, Senior Vice President, Biologics Department, 10.2014 View document
"I think overall the IMPACT Program has helped in a couple of areas. It helped us to realize that how we deploy machines in the region has a significant impact on the total overall cost of a blood drive. And that the support we received from Haemonetics was probably just as vital as the actual program itself.”
William Henry, Executive Director, 06.2011 View document
"This program helped us control and decrease our cost per collection. By utilizing the data collected we have identified the most cost effective mobiles with the right products. This has allowed us to attract the right donors and produce quality products in a cost-effective manner.”
Connie Morris, Executive Director, 08.2011 View document
"The IMPACT Program has allowed us to drill down from information that we had… And having that ability, and the technical and consultative services from Haemonetics, has really allowed us to impact our costs significantly."
Stacy Sime, President and CEO, 04.2011 View document
"Our Haemonetics trainers were top-notch and very easy to work with, while at the same time, they held us to a high level of achievement. I especially appreciated the fact that the focus was not on memorizing mathematical calculations, but rather on how to understand and apply the Six Sigma tools in a highly practical manner. Haemonetics Corporation’s many years of experience in blood collection meant that we never had to explain the subtleties associated with our particular industry."
Gregg Booth, Division Director, Laboratories, 04.2009 View document
After partnering with Haemonetics to implement Six Sigma methodology to improve internal processes, MVRBC achieved an annual savings of more than $700,000 and $420,000 in new revenues, increased their blood supply, and reduced platelet outdating. View document
Through the use of Haemonetics’ consulting services, a large blood center was able to increase their 2RBC collections, boost growth in O- red cell products, improve their donor conversion practices, and expand market penetration. View document
The ACP 215 system is the integral component of the US DoD’s new Strategic Frozen Blood Program that has enabled it to achieve significant improvements and successful results in theaters of operation across the globe.
“It's about letting them know that although this product goes through further manufacturing and a different process than our transfusable products, in the end there is a patient relying on these, just as there is with our transfusable products that impact lives.”
Erin Myers, Director of Source Plasma, BloodSource, 09.2015 View document
“The Haemonetics implementation of eQue in February
2007 and EXPRESS in August 2008 to all ABS Centers
has been a “Great Success”. We have been able to
provide faster service to our donors and better quality
products to fractionators. Donors have increased
their monthly individual donations by an average of
approximately 25%, which brought more revenue to
the company and more plasma to the industry, which
is in great need of this life saving product. We are
grateful that we have such a strong relationship with
Haemonetics, and we hope to continue this in the future.”
Nelli Cherny, RN, BSN, VP QA/RA, 04.2009
© 2011-2017 Haemonetics Corporation • 400 Wood Road • Braintree • MA • 02184